US biopharma Mineralys Therapeutics (Nasdaq: MLYS) has announced positive top-line data from its Phase II Explore-CKD trial evaluating the safety and efficacy of 25mg of lorundrostat in subjects with hypertension and comorbid chronic kidney disease (CKD).
The crossover trial met the primary endpoint and demonstrated clinically-meaningful reductions in both systolic automated office blood pressure and urine albumin-to-creatinine ratio (UACR), and demonstrated a favorable safety and tolerability profile.
Lorundrostat 25mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted decrease at four weeks, while it showed a clinically meaningful decline in the pre-defined endpoint spot UACR of 31%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze